JP2025515470A5 - - Google Patents
Info
- Publication number
- JP2025515470A5 JP2025515470A5 JP2024563188A JP2024563188A JP2025515470A5 JP 2025515470 A5 JP2025515470 A5 JP 2025515470A5 JP 2024563188 A JP2024563188 A JP 2024563188A JP 2024563188 A JP2024563188 A JP 2024563188A JP 2025515470 A5 JP2025515470 A5 JP 2025515470A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr
- domain includes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263335697P | 2022-04-27 | 2022-04-27 | |
| US63/335,697 | 2022-04-27 | ||
| PCT/US2023/019989 WO2023212056A2 (en) | 2022-04-27 | 2023-04-26 | Combination of cytokine fusion proteins with cd8 antigen binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025515470A JP2025515470A (ja) | 2025-05-15 |
| JP2025515470A5 true JP2025515470A5 (cg-RX-API-DMAC7.html) | 2026-05-11 |
Family
ID=88519563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024563188A Pending JP2025515470A (ja) | 2022-04-27 | 2023-04-26 | サイトカイン融合タンパク質とcd8抗原結合分子の併用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250339519A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4514397A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025515470A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250027597A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119546343A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023259161A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3250301A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202400664A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023212056A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230112632A (ko) | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2026162740A1 (en) * | 2025-01-31 | 2026-08-06 | Astrazeneca Ab | Cd8-binding cytokine engager combination therapies |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200306301A1 (en) * | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| JP2020533971A (ja) * | 2017-08-28 | 2020-11-26 | アルター・バイオサイエンス・コーポレーション | Il−15をベースとするil−7及びil−21への融合物 |
| JP7778571B2 (ja) * | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス, インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン-2ポリペプチドと抗原結合分子の融合体 |
| EP4175979A2 (en) * | 2020-07-02 | 2023-05-10 | Inhibrx, Inc. | Polypeptides comprising modified il-2 polypeptides and uses thereof |
| KR20230086765A (ko) * | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
| KR20230112632A (ko) * | 2020-10-23 | 2023-07-27 | 애셔 바이오테라퓨틱스, 인크. | 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합 |
| WO2022245500A1 (en) * | 2021-05-19 | 2022-11-24 | Asher Biotherapeutics, Inc. | Il-21 polypeptides and targeted constructs |
-
2023
- 2023-04-26 CN CN202380050634.5A patent/CN119546343A/zh active Pending
- 2023-04-26 JP JP2024563188A patent/JP2025515470A/ja active Pending
- 2023-04-26 WO PCT/US2023/019989 patent/WO2023212056A2/en not_active Ceased
- 2023-04-26 KR KR1020247039383A patent/KR20250027597A/ko active Pending
- 2023-04-26 AU AU2023259161A patent/AU2023259161A1/en active Pending
- 2023-04-26 CA CA3250301A patent/CA3250301A1/en active Pending
- 2023-04-26 US US18/859,452 patent/US20250339519A1/en active Pending
- 2023-04-26 EP EP23797206.2A patent/EP4514397A4/en active Pending
- 2023-04-27 TW TW112115849A patent/TW202400664A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6216940B2 (ja) | ラクダ科動物由来の抗原結合ポリペプチド | |
| JP2024175003A5 (cg-RX-API-DMAC7.html) | ||
| JP2024009962A5 (cg-RX-API-DMAC7.html) | ||
| JP2024167313A5 (cg-RX-API-DMAC7.html) | ||
| JP2020122013A5 (cg-RX-API-DMAC7.html) | ||
| RU2018146050A (ru) | Биспецифические связывающие белки, которые связывают иммуномодулирующий белок и опухолевый антиген | |
| RU2020124191A (ru) | Анти-tigit антиген-связывающие белки и способы их применения | |
| JP2021524278A5 (cg-RX-API-DMAC7.html) | ||
| JP2024522069A5 (cg-RX-API-DMAC7.html) | ||
| JP2017522892A5 (cg-RX-API-DMAC7.html) | ||
| RU2010150348A (ru) | Антитела к рецептору конечных продуктов глубокого гликирования (rage) и их применение | |
| AR126758A2 (es) | Anticuerpos anti-ly6g6d y métodos de uso | |
| JP2025063183A5 (cg-RX-API-DMAC7.html) | ||
| JP2021520832A5 (cg-RX-API-DMAC7.html) | ||
| RU2004135103A (ru) | Антитела, специфичные к cd22 человека, и их применения в терапии и диагностике | |
| JP2024086870A5 (cg-RX-API-DMAC7.html) | ||
| JP2010524435A5 (cg-RX-API-DMAC7.html) | ||
| HRP20191219T1 (hr) | Molekule protutijela koje imaju specifičnost za ljudski ox40 | |
| RU2018126318A (ru) | Молекулы полиспецифичных антител, имеющие специфичность к tnf-альфа, il-17a и il-17f | |
| RU2003100512A (ru) | Антитела к человеческому мср-1 | |
| JP2022505445A5 (cg-RX-API-DMAC7.html) | ||
| RU2019124709A (ru) | КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА | |
| JP2020522473A5 (cg-RX-API-DMAC7.html) | ||
| JP2022501065A5 (cg-RX-API-DMAC7.html) | ||
| JP2023553694A5 (cg-RX-API-DMAC7.html) |